Bharat Biotech’s intranasal heterologous booster to hit market in Feb first week

According to reports, Bharat Biotech’s intranasal heterologous booster dosage would be accessible on the market only in the first week of February. Bharat Biotech has introduced iNCOVACC (BBV154) as a booster dosage in the nation. Bharat Biotech gained permission from the Central Drugs Standard Control Organization (CDSCO) earlier this month for the use of heterologous booster doses of iNCOVACC.
CoWin still does not have the vaccination.

The pricing of iNCOVACC, according to the business, would be Rs 900 for the private market and Rs 325 for shipments to the Government of India and state governments.

“iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilized SARS-CoV-2 spike protein. This vaccine candidate was evaluated in phases I, II and III clinical trials with successful results.

iNCOVACC has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries.” reads an official statement.

Dr Krishna Ella, Executive Chairman of Bharat Biotech, said, “We have achieved the goals we set for ourselves during this pandemic. We have developed COVAXIN and iNCOVACC, two COVID vaccines from two different platforms, with two different delivery systems. The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up and easy and painless immunization during public health emergencies and pandemics. We thank the Ministry of Health, CDSCO, Dept of Biotechnology, Govt of India, Technology Development Board, and Washington University, St Louis, for their support and guidance.”

Bharat Biotech’s iNCOVACC, a needleless immunisation, will be India’s first of its kind.